Neoadjuvant therapy for PIK3CA-mutated, HER2+ early breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of medications (inavolisib, pertuzumab, trastuzumab, and nab-paclitaxel) given before surgery to shrink tumors in people with HER2-positive early breast cancer that also has a specific gene change (PIK3CA mutation). The goal is to see if this treatment is effective and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of HER2-positive breast cancer that has not been treated yet.
- Your tumor has a PIK3CA gene mutation (tested locally).
- Your breast tumor is at stage cT1b to cT3 and can be measured by ultrasound or MRI.
- You are 18 years or older, with good performance status (ECOG 0-1).
- Your heart function is normal (LVEF above 55%) and you have adequate blood counts and liver/kidney function.
- You are willing to use effective contraception if of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a drug called Inavolisib (a type of targeted therapy) given before surgery for people with early-stage, hormone receptor-positive, HER2-negative breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding Inavolisib to standard endocrine therapy can shrink the tumor more effectively.
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
This trial tests whether a new targeted pill (inavolisib) plus hormone therapy (fulvestrant) can slow or stop breast cancer growth in people whose cancer has a specific genetic change called a PIK3CA mutation. It is for patients whose disease worsened after previous hormone-and-CDK-inhibitor treatment.
This study observes how inavolisib (a new cancer drug) works in patients with a specific type of advanced breast cancer in everyday clinical practice. Researchers will track your medical records, imaging, and lab results over time to understand how well the treatment works and its safety profile.
This study tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) for women with advanced breast cancer that is hormone-receptor positive and HER2-negative, with a specific genetic mutation (PIK3CA). The goal is to see if this combination can shrink or control the cancer better than standard treatments.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.